Literature DB >> 2555041

Neurologic complications in children with soft tissue and osseous sarcoma.

E D Kramer1, D Lewis, B Raney, R Womer, R J Packer.   

Abstract

From 1980 to 1987, 162 consecutive children with soft tissue and osseous sarcoma were reviewed to determine the frequency and types of neurologic complications seen. Neurologic complications occurred in 43 of 162 (26.5%) patients. Children with poorly differentiated sarcomas and rhabdomyosarcoma were more likely to have neurologic complications, which occurred in 39% of patients at risk. The types of complications seen included: metastatic spinal cord compression (11%); symptomatic peripheral neuropathy (10%); intracranial metastatic disease (7.5%); seizures (6%); and acute and chronic methotrexate-related neurologic dysfunction (2.5%). Spinal cord compression frequently occurred early in disease whereas brain metastases was almost always a late finding. Symptomatic peripheral neuropathy occurred primarily in children with rhabdomyosarcoma and Ewing's sarcoma. The advent of increasingly successful therapies for children with sarcoma and the frequency of severe neurologic complications indicate that a heightened level of surveillance for neurologic compromise is required.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2555041     DOI: 10.1002/1097-0142(19891215)64:12<2600::aid-cncr2820641232>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Metastatic spinal cord compression in patients with colorectal cancer.

Authors:  P D Brown; S L Stafford; S E Schild; J A Martenson; D Schiff
Journal:  J Neurooncol       Date:  1999-09       Impact factor: 4.130

2.  Primary Intracerebral Alveolar Soft Part Sarcoma in an 11-Year-Old Girl: Case Report and Review of the Literature.

Authors:  Hakan Emmez; Aydemir Kale; Çelik Sevinç; Alp Özgün Börcek; Güldal Yilmaz; Memduh Kaymaz; Ömer Uluoğlu; Aydın Paşaoğlu
Journal:  NMC Case Rep J       Date:  2014-09-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.